Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Mallinckrodt
Express Scripts
Baxter
Daiichi Sankyo
US Army

Generated: September 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,649,456

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,649,456
Title:Nasal administration
Abstract: A delivery device for and method of delivering a powdered substance, in particular a triptan, such as sumatriptan, to the posterior region of a nasal cavity of a subject, in particular for the treatment of headaches, for example, cluster headaches and migraine, and neuropathic pain, the delivery device comprising: a nosepiece (47) for insertion into a nasal cavity of a subject through which the powdered substance is delivered to the posterior region of the nasal cavity of the subject, in particular the upper posterior two thirds of the nasal cavity; and a substance supply unit (16) which is operable to deliver the powdered substance through the nosepiece (47).
Inventor(s): Djupesland; Per Gisle (Oslo, NO), Hafner; Roderick Peter (Swindon, GB)
Assignee: OptiNose AS (Oslo, NO)
Application Number:12/594,365
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery; Device; Dosage form;

Drugs Protected by US Patent 9,649,456

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Avanir Pharms ONZETRA XSAIL sumatriptan succinate POWDER;INHALATION 206099-001 Jan 27, 2016 RX Yes Yes   Try a Free Trial   Try a Free Trial Y TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY   Try a Free Trial
Avanir Pharms ONZETRA XSAIL sumatriptan succinate POWDER;INHALATION 206099-001 Jan 27, 2016 RX Yes Yes   Try a Free Trial   Try a Free Trial Y ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE   Try a Free Trial
Avanir Pharms ONZETRA XSAIL sumatriptan succinate POWDER;INHALATION 206099-001 Jan 27, 2016 RX Yes Yes   Try a Free Trial   Try a Free Trial Y ACUTE TREATMENT OF MIGRAINE   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,649,456

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0706744.0Apr 5, 2007
PCT Information
PCT FiledApril 07, 2008PCT Application Number:PCT/GB2008/001226
PCT Publication Date:October 16, 2008PCT Publication Number: WO2008/122795

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Chubb
Fish and Richardson
Baxter
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.